Compare SOLS & MEDP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SOLS | MEDP |
|---|---|---|
| Founded | 2025 | 1992 |
| Country | United States | United States |
| Employees | 4400 | N/A |
| Industry | Aerospace | Biotechnology: Commercial Physical & Biological Resarch |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.9B | 14.9B |
| IPO Year | N/A | 2016 |
| Metric | SOLS | MEDP |
|---|---|---|
| Price | $81.15 | $521.70 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 4 | 13 |
| Target Price | $79.25 | ★ $498.25 |
| AVG Volume (30 Days) | ★ 1.7M | 278.7K |
| Earning Date | 05-06-2026 | 04-22-2026 |
| Dividend Yield | ★ 0.38% | N/A |
| EPS Growth | N/A | ★ 20.98 |
| EPS | N/A | ★ 15.28 |
| Revenue | N/A | N/A |
| Revenue This Year | $6.46 | $13.19 |
| Revenue Next Year | $5.46 | $7.75 |
| P/E Ratio | $54.31 | ★ $33.73 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $40.43 | $250.05 |
| 52 Week High | $84.44 | $628.92 |
| Indicator | SOLS | MEDP |
|---|---|---|
| Relative Strength Index (RSI) | 58.51 | 64.29 |
| Support Level | $69.12 | $489.09 |
| Resistance Level | $83.38 | $547.15 |
| Average True Range (ATR) | 2.87 | 17.12 |
| MACD | 0.12 | 4.23 |
| Stochastic Oscillator | 74.44 | 92.73 |
Solstice Advanced Materials is a diversified specialty chemicals company created in late 2025 after being spun off from Honeywell. It sells chemicals and materials to a wide range of end markets. Its largest product category is refrigerants used in heating, ventilation and air conditioning systems, and autos, where Solstice sells low global warming potential refrigerants. The company also sells materials used for building and construction, semiconductor production, healthcare packaging, and defense. Additionally, Solstice runs the only US uranium conversion business currently in operation.
Medpace is a late-stage contract research organization that provides full-service drug-development and clinical trial services to small and midsize biotechnology, pharmaceutical, and medical device firms. It also offers ancillary services, including bioanalytical laboratory services and imaging capabilities. The company was founded over 30 years ago and has more than 5,400 employees across 40 countries. Medpace is headquartered in Cincinnati, Ohio, and its operations are primarily based in the US, with additional presence in Europe, Asia, South America, Africa, and Australia. Cinven, a global private equity firm, acquired Medpace for $915 million in 2014 and exited its investment in 2018.